For a patient on aspirin and prasugrel undergoing an elective lower‑extremity angiogram, how should the antiplatelet therapy be managed?

Management of Antiplatelet Therapy for Elective Lower‑Extremity Angiography

For a patient on aspirin and prasugrel undergoing elective lower‑extremity angiography, continue aspirin throughout the procedure and discontinue prasugrel 7 days before the angiogram. 1

Aspirin Management

• Continue aspirin (75–100 mg daily) throughout the peri‑procedural period without interruption. 2, 1
• The thrombotic risk of stopping aspirin exceeds the modest bleeding risk associated with diagnostic angiography, which is a low‑bleeding‑risk procedure. 2, 1
• Aspirin's bleeding risk during diagnostic angiography is minimal and acceptable; its cardiovascular protective benefit clearly outweighs any procedural bleeding increase. 1

Prasugrel Management

• Stop prasugrel at least 7 days before the elective lower‑extremity angiogram. 3, 2, 1
• Prasugrel requires a longer discontinuation interval (7 days) compared to clopidogrel or ticagrelor (5 days) because it provides more potent and prolonged platelet inhibition. 1, 4
• The FDA label explicitly states: "When possible, discontinue prasugrel at least 7 days prior to any surgery." 4
• Pharmacodynamic studies confirm that ≥75% of patients return to baseline platelet reactivity by day 7 after prasugrel discontinuation, supporting the 7‑day recommendation. 5

Evidence Supporting Differential Management

• In the TRITON‑TIMI‑38 trial, patients receiving prasugrel before invasive procedures experienced significantly higher rates of major bleeding, platelet transfusions, and surgical re‑explorations compared with clopidogrel, providing Level A evidence of increased bleeding risk. 3, 1
• The French Working Group on Perioperative Haemostasis (GIHP) and French Study Group on Thrombosis and Haemostasis (GFHT) issued strong agreement recommendations for continuing aspirin while discontinuing prasugrel 7 days before elective procedures. 3

Special Circumstances Requiring Modified Management

If the patient has a recent coronary stent, the timing must be adjusted based on stent age:

• < 1 month after any stent: Postpone the elective angiogram if possible; if unavoidable, consider continuing both aspirin and prasugrel after multidisciplinary cardiology consultation. 2
• 1–6 weeks after stent: Maintain both agents when possible; if one must be stopped, keep aspirin and discontinue prasugrel only after cardiology consultation. 2
• 6 weeks–3 months after stent: Either continue both agents or stop prasugrel while maintaining aspirin, guided by stent type and bleeding risk. 2
• 3–12 months after stent: Stop prasugrel 7 days before the procedure; continue aspirin. 2
• > 12 months after stent: Apply standard management (stop prasugrel 7 days, continue aspirin). 2

Post‑Procedural Resumption

• Resume aspirin within 24 hours after the angiogram if hemostasis is satisfactory; same‑day restart is acceptable when feasible. 2
• Restart prasugrel 24–72 hours post‑procedure once adequate hemostasis is confirmed. 2
• A loading dose of prasugrel (60 mg) may be considered in high‑risk patients with recent stents, though no definitive recommendation exists. 2

Critical Pitfalls to Avoid

• Never discontinue both aspirin and prasugrel simultaneously in patients with coronary stents placed within the past 12 months, as this dramatically increases stent‑thrombosis mortality. 2, 6
• Do not use heparin or low‑molecular‑weight heparin as bridging therapy to substitute for antiplatelet agents; anticoagulants do not prevent arterial or stent thrombosis and actually increase bleeding risk. 2, 6
• Avoid peri‑procedural NSAIDs in patients on dual antiplatelet therapy, as they increase bleeding risk 2–3‑fold. 2
• Do not extend the prasugrel discontinuation period beyond 7 days, as longer delays increase thrombotic risk without additional hemostatic benefit. 2

Regional Anesthesia Considerations (if applicable)

• Peripheral nerve blocks with low bleeding risk (femoral block, popliteal sciatic block) can be performed on dual antiplatelet therapy according to benefit–risk assessment. 3, 2
• Deep peripheral nerve blocks (infraclavicular, parasacral sciatic, posterior lumbar plexus) are contraindicated on prasugrel unless it has been discontinued for the full 7‑day interval. 3, 2
• Neuraxial anesthesia (spinal/epidural) is absolutely contraindicated on prasugrel unless discontinued for 7 days; aspirin alone is not a contraindication. 3, 2
• All blocks should be performed using ultrasound guidance by experienced operators. 3, 2